Your browser doesn't support javascript.
loading
Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience.
Mello Filho, Paulo; Andrade, Gabriel; Maia, Andre; Maia, Mauricio; Biccas Neto, Laurentino; Muralha Neto, Acacio; Moura Brasil, Oswaldo; Minelli, Eduardo; Dalloul, Claudio; Iglicki, Matias.
Afiliação
  • Mello Filho P; Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
  • Andrade G; Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil, drgabrielandrade@gmail.com.
  • Maia A; Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
  • Maia M; Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
  • Biccas Neto L; Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil.
  • Muralha Neto A; Department of Ophthalmology, Rio de Janeiro State University, Rio de Janeiro, Brazil.
  • Moura Brasil O; Brazilian Institute of Ophthalmology, Rio de Janeiro, Brazil.
  • Minelli E; HCLOE Clinic, São Paulo, Brazil.
  • Dalloul C; D'Olhos Hospital, São José do Rio Preto, Brazil.
  • Iglicki M; Retina Private Office, Buenos Aires, Argentina.
Ophthalmologica ; 241(1): 9-16, 2019.
Article em En | MEDLINE | ID: mdl-30408801
INTRODUCTION: There are few real-life studies on the intravitreal 0.7-mg dexamethasone implant for the treatment of diabetic macular edema (DME) conducted in Latin America. We aimed to assess the effectiveness and safety of this implant in clinical practice. METHODS: Twenty-seven centers from Brazil and one from Argentina provided information on patients with DME treated with Ozurdex. The efficacy outcome variables were best-corrected visual acuity (BCVA) in Snellen and central retinal thickness (CRT). Safety was assessed by the elevation in intraocular pressure (IOP), occurrence of cataracts, and adverse events. RESULTS: A total of 329 eyes (both treated cases and naïve eyes) from 282 patients underwent treatment. The time since diagnosis of DME ranged from 1 to 156 months. The median BCVA was 0.7 logMAR/50 letters at baseline and 0.3 logMAR/70 letters after treatment (both p < 0.001). Median CRT values decreased from 425 µm at baseline to 270 µm after treatment (p < 0.001). Increases in IOP of at least 10 mm Hg were observed in 7.4% of eyes, and 4% of eyes had cataract evolution. No cases of endophthalmitis were reported. CONCLUSION: These real-life results suggest that the intravitreal dexamethasone implant is effective and safe for eyes with DME.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dexametasona / Acuidade Visual / Edema Macular / Retinopatia Diabética Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ophthalmologica Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dexametasona / Acuidade Visual / Edema Macular / Retinopatia Diabética Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ophthalmologica Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça